Phase II study of TS-1 / oxaliplatin(G-SOX) plus bevacizumab treatment for elderly advanced colorectal cancer patients.(GIANTS study)
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: TS-1 administered for 14 days followed by 7 days rest according to body surface area. L-OHP is administered intravenously in 100 mg/m2 at day 1. Bevacizumab is administered intravenously in 7.5 mg/kg at day 1 Cycles are repeated every 3 weeks Primary outcome(s): progression-free survival(PFS) Study Design: Single arm Non-randomized
创建时间：
2012-11-15
